1. Wiggins JB, Rajapakse R. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009. 5:1279–1284.
2. Tursi A. Balsalazide in treating colonic diseases. Expert Opin Drug Metab Toxicol. 2009. 5:1555–1563.
3. Muzzi A, Ciani F, Bianchini D, Festini G, Volpe C. Adverse pulmonary effects of mesalamine. Chest. 1995. 108:1181.
4. Park JE, Hwangbo Y, Chang R, Chang YW, Jang JY, Kim BH, et al. Mesalazine-induced eosinophilic pneumonia in a patient with Crohn's disease. Korean J Gastroenterol. 2009. 53:116–120.
5. Tanigawa K, Sugiyama K, Matsuyama H, Nakao H, Kohno K, Komuro Y, et al. Mesalazine-induced eosinophilic pneumonia. Respiration. 1999. 66:69–72.
6. Bitton A, Peppercorn MA, Hanrahan JP, Upton MP. Mesalamine-induced lung toxicity. Am J Gastroenterol. 1996. 91:1039–1040.
7. Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis. 2003. 9:308–315.
8. Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore). 1993. 72:151–183.
9. Yano S, Kobayashi K, Kato K, Nishimura K. A limited form of Wegener's granulomatosis with bronchiolitis obliterans organizing pneumonitis-like variant in an ulcerative colitis patient. Intern Med. 2002. 41:1013–1015.
10. Kasuga A, Mandai Y, Katsuno T, Sato T, Yamaguchi T, Yokosuka O. Pulmonary complications resembling Wegener's granulomatosis in ulcerative colitis with elevated proteinase-3 anti-neutrophil cytoplasmic anti-body. Intern Med. 2008. 47:1211–1214.
11. Salerno SM, Ormseth EJ, Roth BJ, Meyer CA, Christensen ED, Dillard TA. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis. Chest. 1996. 110:556–559.
12. Stebbing J, Askin F, Fishman E, Stone J. Pulmonary manifestations of ulcerative colitis mimicking Wegener's granulomatosis. J Rheumatol. 1999. 26:1617–1621.
13. Meyer KC, Raghu G. Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J. 2011. 38:761–769.
14. Khan A, Lawson CA, Quinn MA, Isdale AH, Green MJ. Successful treatment of ANCA-negative Wegener's granulomatosis with rituximab. Int J Rheumatol. 2010. 2010:846063.